• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Brainstorm Cell Therapeutics Inc.

    7/3/25 4:31:22 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCLI alert in real time by email
    S-8 1 tm2519000d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on July 3, 2025


    Registration No. 333-       

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

    BRAINSTORM CELL THERAPEUTICS INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 20-7273918

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    1325 Avenue of Americas, 28th Floor, New York, NY, 10019
    (Address of Principal Executive Offices, Zip Code)

     

    2014 Stock Incentive Plan

    2014 Global Share Option Plan

    (Full title of the plan)

     

    Chaim Lebovits

    President and Chief Executive Officer

    Brainstorm Cell Therapeutics Inc.

    1325 Avenue of Americas, 28th Floor

    New York, NY 10019

    (Name and address of agent for service)

     

    (201) 488-0460

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Mitchell S. Bloom, Esq.

    Mayan Katz, Esq.

    Goodwin Procter LLP

    100 Northern Ave

    Boston, Massachusetts 02210

    (617) 570-1000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
           
    Non-accelerated filer   x   Smaller reporting company   x
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (this “Registration Statement”) is being filed to register an additional 2,533,333 shares of common stock, par value $0.00005 per share (“Common Stock”), of Brainstorm Cell Therapeutics Inc. (the “Registrant”) reserved under the Registrant’s 2014 Stock Incentive Plan and the 2014 Global Share Option Plan, each as amended through June 25, 2025 (as amended, collectively, the “2014 Plans”), including (i) additional 533, 333 shares of Common Stock (as adjusted to reflect the reverse stock split effected in October 2024) reserved under the 2014 Plans pursuant to the amendments thereto adopted by the stockholders on September 16, 2024, and (ii) additional 2,000,000 shares of Common Stock reserved under the 2014 Plans pursuant to the amendments thereto adopted by the stockholders on June 25, 2025. This Registration Statement registers additional securities of the same class as other securities of the Registrant for which the registration statements filed on Form S-8 relating to the 2014 Plans (File No. 333-198391, File No. 333-213714, File No. 333-228981 and File No. 333-261598) of the Registrant are effective. The information contained in the Registrant’s registration statements on Form S-8 relating to the 2014 Plans (File No. 333-198391, File No. 333-213714, File No. 333-228981 and File No. 333-261598) is hereby incorporated by reference pursuant to General Instruction E of Form S-8, except with respect to Item 8. Exhibits thereof.

     

     

     

    Part II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

     

     

    Item 8. Exhibits.

     

    The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement, and the contents of the Exhibit Index are incorporated herein by reference.

     

    EXHIBIT INDEX

     

                Incorporated by Reference
    Exhibit
    Number
      Exhibit Description   Filed
    Herewith
      Form   SEC File /
    Registration
    Number
          Exhibit   Filing Date
                               
    4.1   Certificate of Incorporation of Brainstorm Cell Therapeutics Inc.       Definitive Schedule 14A   333-61610       Appendix B   11/20/2006
    4.2   Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated September 15, 2014.       8-K   000-54365       3.1   09/16/2014
    4.3   Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated August 31, 2015.       8-K   001-366641     3.1   09/04/2015
    4.4   Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 16, 2024.       8-K   001-366641       3.1   09/16/2024
    4.5   Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 30, 2024.       8-K   001-366641       3.1   10/01/2024
    4.6   ByLaws of Brainstorm Cell Therapeutics Inc.        Definitive Schedule 14A   333-61610       Appendix C   11/20/2006
    4.7   Amendment No. 1 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of March 21, 2007.       8-K   333-61610       3.1   03/27/2007
    4.8   Amendment No. 2 to the Bylaws of Brainstorm Cell Therapeutics Inc., dated as of April 20, 2025       8-K   333-61610       3.1   04/21/2025
    5.1   Opinion of Goodwin Procter LLP   X                    
    23.1   Consent of Goodwin Procter LLP (included in opinion of counsel filed as Exhibit 5.1)   X                    
    23.2   Consent of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network.   X                    
    24   Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)   X                    

     

     

     

    99.1   Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       8-K   000-54365       10.1   08/15/2014
    99.2   Amendment No. 1 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       Definitive Schedule 14A   000-36641       Appendix A   05/11/2016
    99.3   Amendment No. 2 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       8-K   000-36641       10.1   11/30/2018
    99.4   Amendment No. 3 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       Definitive Schedule 14A   000-36641       Appendix A   10/01/2020
    99.5   Amendment No. 4 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       8-K   000-36641       10.5   09/16/2024
    99.6   Amendment No. 5 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan       8-K   000-36641       10.6   06/25/2025
    99.7   Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       8-K   000-54365       10.2   08/15/2014
    99.8   Amendment No. 1 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       Definitive Schedule 14A   000-36641       Appendix B   05/11/2016
    99.9   Amendment No. 2 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       8-K   000-36641       10.2   11/30/2018
    99.10   Amendment No. 3 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       Definitive Schedule 14A   000-36641       Appendix B   10/01/2020
    99.11   Amendment No. 4 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       8-K   000-36641       10.10   09/16/2024
    99.12   Amendment No. 5 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan       8-K   000-36641       10.12   06/25/2025
    107   Filing Fee table   X                    

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of New York, State of New York, on July 3, 2025.

     

      BRAINSTORM CELL THERAPEUTICS INC.
         
      By: /s/ Chaim Lebovits
        Chaim Lebovits
        President and Chief Executive Officer

     

    Each person whose signature appears below constitutes and appoints Chaim Lebovits, Uri Yablonka and Alla Patlis, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

    Name   Title   Date
             

    /s/ Chaim Lebovits

    Chaim Lebovits

     

    President and Chief Executive Officer

    (Principal Executive Officer)

      July 3, 2025
             

    /s/ Alla Patlis

    Alla Patlis

     

    Interim Chief Financial Officer

    (Principal Financial and Accounting Officer)

      July 3, 2025
             

    /s/ Irit Arbel

    Irit Arbel

      Director   July 3, 2025
             

    /s/ Nir Naor

    Nir Naor

      Director   July 3, 2025
             

    /s/ Jacob Frenkel

    Jacob Frenkel

      Director   July 3, 2025
             

    /s/ Anthony Polverino

    Anthony Polverino

      Director   July 3, 2025
             

    /s/ Uri Yablonka

    Uri Yablonka

      Director   July 3, 2025
             

    /s/ Menghisteab Bairu

    Menghisteab Bairu

      Director   July 3, 2025
             

    /s/  Stacy Lindborg

    Stacy Lindborg

      Director   July 3, 2025

     

     

    Get the next $BCLI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BCLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

      NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn® (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The EAP enrolled 10 participants who had previously completed the Phase 3 clinical trial. The analysis reviewed survival from the time of first symptom onset through participation in the Phase 3 trial, EAP Periods 1 and 2, followed by additional survival data collected through publicly available records. EAP participants presented at the start of the Phase

      6/16/25 8:30:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

      NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. This partnership supports

      5/27/25 7:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

      Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

      5/19/25 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Dagher Ibrahim B. was granted 50,000 shares, increasing direct ownership by 297% to 66,849 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/7/25 4:11:08 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: New insider Dagher Ibrahim B. claimed ownership of 505,742 shares (SEC Form 3)

      3/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/7/25 4:10:10 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President & CEO Lebovits Chaim was granted 120,000 shares, increasing direct ownership by 148% to 200,960 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/3/25 5:36:42 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brainstorm Cell upgraded by Maxim Group

      Maxim Group upgraded Brainstorm Cell from Hold to Buy

      2/5/21 8:55:41 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brainstorm Cell Therapeutics upgraded by Maxim Group with a new price target

      Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00

      2/4/21 1:51:23 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    SEC Filings

    See more
    • SEC Form S-8 filed by Brainstorm Cell Therapeutics Inc.

      S-8 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      7/3/25 4:31:22 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc.

      S-3 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      6/25/25 4:39:53 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      6/25/25 4:31:17 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

      Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

      5/19/25 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We h

      5/15/25 4:05:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

      NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has rescheduled the release of its financial results for the first quarter ended March 31, 2025, to post-market close today, May 15. In addition, the Company has rescheduled its previously announced investor conference call, which will now take place on Monday, May 19, 2025, at 8:30 a.m. Eastern Time. BrainStorm's President & Chief Executive Officer, Chaim Lebovits, will present a corporate update to be followed by Q&A. Joining Mr. Lebovits to answer investment community questions will be Haro Hart

      5/15/25 7:30:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Leadership Updates

    Live Leadership Updates

    See more
    • BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

      Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.     Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil

      6/20/24 6:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

      Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.  He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin

      7/12/23 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

      NEW YORK, June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and member of its Governance, Nomination and Compensation Committee (GNC), effective June 20. Mr. Naor is replacing Mr. Malcolm Taub, who will retire from the same roles after 14 years of service on the Company's board of directors. "We welcome the addition of Nir as a new independent board member, and we are confident that his impressive corporate experience in both the U.S. and Europe will add further

      6/20/23 9:06:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Lebovits Chaim bought $11,308 worth of shares (23,836 units at $0.47), decreasing direct ownership by 93% to 80,960 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      10/2/24 8:00:14 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: President & CEO Lebovits Chaim bought $7,774 worth of shares (15,000 units at $0.52), increasing direct ownership by 1% to 1,164,865 units (SEC Form 4)

      4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      7/31/24 4:09:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: President & CEO Lebovits Chaim bought $30,475 worth of shares (50,000 units at $0.61), increasing direct ownership by 5% to 1,149,865 units (SEC Form 4)

      4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      7/31/24 4:08:32 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

      SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      11/14/24 3:24:53 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

      SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      11/13/24 7:55:51 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

      SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      2/12/24 10:06:24 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care